secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-09-15T23:59:59+00:00
Accession:  0001104659-23-100996
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends PDUFA date for Iovance's lifileucel BLA to Feb 24, 2024 due to resource constraints
--------------------------------------------------------------------------------

- FDA extended PDUFA target action date for lifileucel BLA from prior to February 24, 2024, citing resource constraints.
- No major review issues; all pre-approval inspections of clinical sites and manufacturing facilities completed successfully.
- No advisory committee meeting planned; Priority Review and RMAT designation remain intact.
- FDA agreed to work with Iovance to expedite remaining review, potentially allowing earlier approval.
- Lifileucel seeks accelerated approval for advanced melanoma with no currently FDA approved therapies in that setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923100996/0001104659-23-100996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923100996/tm2326192d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-100996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer